Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Syngeneic Modeling of Chimeric Antigen Receptor T Cell Therapies: Optimizing Murine Constructs and Overcoming Barriers to Efficacy
FY 2025-26
Summary
Background: Chimeric antigen receptor (CAR)-T cell therapy is a cancer therapy where the body’s immune cells are modified to better recognize and kill tumour cells. Current research studies these therapies in mice without an immune system. Not only do these models lack immune cells that can inhibit the therapeutic CAR-T cell response, they also poorly represent safety risks that occur from overactivation of the immune system by these therapies. Thus, current approaches for studying CAR-T therapy frequently overestimate therapeutic efficacy and understate toxicity risks. This project aims to develop a more biologically relevant model for studying CAR-T therapies using mice equipped with complete immune systems.
Aim 1- Improving CAR-T therapy using mouse models: Literature suggests that targeted modifications to specific regions of the CAR can improve function, which we seek to leverage to enhance efficacy. Using a fully mouse-based model system, we will determine the extent to which structural changes to stimulatory regions of CAR affect therapeutic ability while also studying effects on safety.
Aim 2- Enhancing CAR-T response through vaccination: Studies have shown that using a vaccine to boost activation through the normal T cell receptor (TCR) can enhance killing ability on top of the CAR. To create these dual-specific CAR-T cells, we will vaccinate mice to generate T cells with tumour-specific TCRs before re-engineering them to also express a CAR. We will test whether the TCR response synergizes with the CAR response to kill cancer cells more efficaciously.
Significance: This mouse-based system for studying CAR-T therapy will allow us to evaluate both safety and efficacy with greater biological relevance to support translation of this therapy into patients.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573065
Name
Rukunuddin Shahrbano
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Syngeneic Modeling of Chimeric Antigen Receptor T Cell Therapies: Optimizing Murine Constructs and Overcoming Barriers to Efficacy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Chimeric Antigen Receptor (Car)-T Cell Therapy; Immunosuppressive Tumor Microenvironment; Oncolytic Viral Boosting; Solid Tumors; Syngeneic Murine Models
Abstract
Background: Chimeric antigen receptor (CAR)-T cell therapy is a cancer therapy where the body’s immune cells are modified to better recognize and kill tumour cells. Current research studies these therapies in mice without an immune system. Not only do these models lack immune cells that can inhibit the therapeutic CAR-T cell response, they also poorly represent safety risks that occur from overactivation of the immune system by these therapies. Thus, current approaches for studying CAR-T therapy frequently overestimate therapeutic efficacy and understate toxicity risks. This project aims to develop a more biologically relevant model for studying CAR-T therapies using mice equipped with complete immune systems.
Aim 1- Improving CAR-T therapy using mouse models: Literature suggests that targeted modifications to specific regions of the CAR can improve function, which we seek to leverage to enhance efficacy. Using a fully mouse-based model system, we will determine the extent to which structural changes to stimulatory regions of CAR affect therapeutic ability while also studying effects on safety.
Aim 2- Enhancing CAR-T response through vaccination: Studies have shown that using a vaccine to boost activation through the normal T cell receptor (TCR) can enhance killing ability on top of the CAR. To create these dual-specific CAR-T cells, we will vaccinate mice to generate T cells with tumour-specific TCRs before re-engineering them to also express a CAR. We will test whether the TCR response synergizes with the CAR response to kill cancer cells more efficaciously.
Significance: This mouse-based system for studying CAR-T therapy will allow us to evaluate both safety and efficacy with greater biological relevance to support translation of this therapy into patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rukunuddin, Shahrbano
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~